It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...
A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.
Morgan Wallen Last week Weeks at no. 1 Weeks on chart Big Loud/Mercury/Republic Gains In Performance Week of February 15, 2025 click to see more Big Loud/Mercury/Republic ...
Laufey Last week Weeks at no. 1 Weeks on chart Laufey/AWAL Greatest gainer this week Gains In Performance Week of February 15, 2025 click to see more ...